Zacks Research Upgrades Autonomix Medical (NASDAQ:AMIX) to “Hold”

Autonomix Medical (NASDAQ:AMIX) was upgraded by investment analysts at Zacks Research to a “hold” rating in a note issued to investors on Tuesday,Zacks.com reports.

Other equities analysts also recently issued research reports about the company. Weiss Ratings upgraded Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday, May 18th. Maxim Group cut their price objective on Autonomix Medical from $5.00 to $2.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $2.00.

Autonomix Medical Stock Down 4.6%

AMIX stock opened at $0.39 on Tuesday. Autonomix Medical has a 52-week low of $0.20 and a 52-week high of $2.64. The firm has a market cap of $2.71 million, a P/E ratio of -0.11 and a beta of -1.43. The company’s 50-day simple moving average is $0.38 and its 200-day simple moving average is $0.50.

About Autonomix Medical

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.